Across transfusion-dependent anemias Unlock the Benefits of Total Body Iron Chelation With Once-daily Oral EXJADE
T2 improvements above the prevention threshold in mild-moderate cardiac iron overloaded patients with beta-thalassemia

TOOLS & RESOURCES

Learn more about Exjade

Learn more about EXJADE

Useful overview of relevant information for physicians new to EXJADE.

Learn more
Mechanism of Action

Mechanism of Action

Clinical animations highlighting the Exjade chelation process.

Learn more
Safety Profile Across Anemia

Safety Profile Across Anemias

Several studies have demonstrated the safety of EXJADE.

Learn more
IPSS Calculator

IPSS calculator

Calculate estimated median survival for patients with MDS.

Learn more
NON-TRANSFUSION-DEPENDENT
THALASSEMIA
TRANSFUSION-
DEPENDENT
THALASSEMIA
LOWER-RISK
MYELODYSPLASTIC
SYNDROME
SICKLE CELL
DISEASE
APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

  • in patients with beta thalassemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years
  • in patients with beta thalassemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older
  • in patients with other anemias aged 2 years and older

EXJADE is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non–transfusion-dependent thalassemia syndromes aged 10 years and older.

Theme Template for Bootstrap